
OptiNose (OPTN) Stock Forecast & Price Target
OptiNose (OPTN) Analyst Ratings
Bulls say
OptiNose Inc. demonstrates a markedly positive financial outlook, with projected revenue for XHANCE anticipated to rise from $94.7 million in 2024 to $389.2 million by 2032, highlighting the product's significant growth potential in treating chronic rhinosinusitis (CS) and nasal polyps. The company has optimized its sales and distribution strategies, resulting in a substantial reduction of over 30% in operating expenses in 2023 compared to the previous year, indicating enhanced business efficiency while maintaining prescription volume. Furthermore, successful trial outcomes, including statistically significant symptom improvement and potential label expansion for XHANCE, position the company advantageously in a market where CS is diagnosed considerably more frequently than nasal polyps, thereby broadening its commercial reach.
Bears say
OptiNose Inc. faces several fundamental challenges that contribute to a negative outlook on its stock, particularly concerning the market potential for its primary product, XHANCE. The company risks failing to achieve peak commercial revenue projections due to limitations related to market size, penetration rates, and pricing dynamics, along with the potential inability to secure essential capital resources for ongoing operations. Additionally, challenges related to intellectual property protection and a limited focus on specialty prescription growth could further hinder the company's competitive positioning and overall commercial success.
This aggregate rating is based on analysts' research of OptiNose and is not a guaranteed prediction by Public.com or investment advice.
OptiNose (OPTN) Analyst Forecast & Price Prediction
Start investing in OptiNose (OPTN)
Order type
Buy in
Order amount
Est. shares
0 shares